Novartis announced today that the European Commission (EC) has approved Cosentyx (secukinumab) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to glucocorticoids or who experience relapse during glucocorticoid taper. (GlobeNewswire) - Oct 21, 2026 - "Supported by data from the Phase III REPLENISH trial, the Cosentyx recommended dose for adults with PMR is 150 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2, 3, and 4, followed by monthly maintenance dosing, in combination with a tapering course of glucocorticoids, after which Cosentyx can be continued as monotherapy."
EMA approval • Immunology • Polymyalgia Rheumatica
|